News and industry insights on Contract development and manufacturing services for chemicals, particularly in pharmaceuticals and specialties.
CDMOs expanded capacity. WuXi Biologics completed the topping‑out of its modular Drug Product facility in Singapore and progressed the Chengdu microbial commercial site. Evonik plans €80 million to expand biotech drug‑substance capacity in Slovakia focused on downstream processing for complex ingredients.
Quality and market access advanced. WuXi Biologics secured UK MHRA GMP certification for ophthalmic biologics and South Korea MFDS certification enabling end‑to‑end supply. AGC Biologics’ Seattle site gained Anvisa GMP approval; its support for Waskyra™ gene therapy reached U.S. and EU authorization.
Complex‑modality pipelines drove CDMO engagements. WuXi Biologics signed a license and research service agreement with Vertex for a trispecific T‑cell engager and partnered with Earendil Labs, Sinorda Biomedicine and HanchorBio on bispecifics, ADCs and fusion proteins. AGC Biologics advanced NN4101 bispecific antibody development and GMP production and will manufacture KTP‑001.
Platform and process innovations expanded services. WuXi Biologics launched the PatroLab digital twin platform; WACKER introduced Contract Research Services for nucleic‑acid medicines. Aptar Pharma reported preclinical proof‑of‑concept for intranasal and pulmonary GLP‑1 delivery. Evonik earned awards for EUDRAGIT polymers and EUDRACAP colon‑targeting capsules, and Asahi Kasei licensed precision ADC technology.
ESG performance remained prominent. WuXi Biologics featured in the S&P Global Sustainability Yearbook (China), repeated the CDP Supplier Engagement A‑List, and earned EcoVadis Platinum and ISO 20400 certification. AGC’s agrochemical CDMO won a Syngenta Supplier Award for Waste Reduction. Meanwhile, SEQENS sought a buyer for CELLforCURE’s Les Ulis site; public financing backed Biovac’s end‑to‑end vaccine facility in South Africa.
